Do Ozempic and Wegovy reduce inflammation as well as support weight loss, and what does the evidence show in Europe?

Ozempic and Wegovy explained: semaglutide, GLP-1 receptor agonists, weight reduction, inflammatory markers, and cardiometabolic risk.

In this episode, we review research suggesting semaglutide may influence inflammatory pathways in addition to promoting weight loss, and how doctors interpret these findings under EU medical guidance.

You’ll learn:

• How GLP-1 receptor agonists improve glucose regulation and appetite control

• Why weight loss itself can reduce systemic inflammation

• The role of markers such as C-reactive protein (CRP)

• Evidence linking semaglutide to cardiovascular risk reduction

• The difference between direct anti-inflammatory effects and ...